These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37533220)

  • 1. Proper Sequencing of Treatment for Castrate Resistant Prostate Cancer.
    Shore ND; Cookson MS
    Urol Pract; 2014 May; 1(1):2-6. PubMed ID: 37533220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases.
    Wen L; Valderrama A; Costantino ME; Simmons S
    Am Health Drug Benefits; 2019 May; 12(3):142-149. PubMed ID: 31346366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapeutic options in metastatic castration-resistant prostate cancer.
    Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
    Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
    Fujimoto N
    Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
    Cassinello J; Arranz JÁ; Piulats JM; Sánchez A; Pérez-Valderrama B; Mellado B; Climent MÁ; Olmos D; Carles J; Lázaro M
    Clin Transl Oncol; 2018 Jan; 20(1):57-68. PubMed ID: 29134562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
    Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
    Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatment for metastatic prostate cancer.
    Gravis G
    Asian J Urol; 2019 Apr; 6(2):162-168. PubMed ID: 31061802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
    Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G
    Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sequencing and combination of agents in castration resistant prostate cancer.].
    Ojeda AV; Ledo MJ; Alvarez-Ossorio JL
    Arch Esp Urol; 2018 Sep; 71(8):711-720. PubMed ID: 30319131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Castration-resistant prostate cancer: AUA Guideline.
    Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
    J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in emerging therapies for advanced prostate cancer.
    Oudard S
    Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Imamura Y; Sadar MD
    Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment sequencing in metastatic castrate-resistant prostate cancer.
    Sartor O; Gillessen S
    Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.